Posts

Posted on

Quotient Builds Business Momentum with Industry Shift to Digital

Quotient Builds Business Momentum with Industry Shift to Digital

After a year in which accelerated consumer trends led to increased revenues, expansion into new verticals and key employee hires, company looks to continue omnichannel success

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Quotient (NYSE: QUOT), the leading digital media and promotions technology company, is primed to build upon last year’s exciting growth that was fueled by the industry’s shift to digital. The shift was hastened at a time when the nation worked, shopped, cooked and schooled largely from home.

Key trends driving revenue include the acceleration of digital coupons, the growing need for first- and second-party data and consumers’ prevailing preference for a hybrid of both digital and physical shopping. Last year was the first time that digital coupon redemptions surpassed paper coupon redemptions in the US, a shift that Quotient helped pioneer and continues to champion. And as the advertising industry prepares for a major disruption due to the changing dynamics of third-party cookies use, Quotient is less affected and well positioned with solutions powered by first- and second-party data.

With a growing suite of omnichannel capabilities powered by exclusive shopper data, Quotient is focused on helping brands and retailers connect with their audiences and provide them with value wherever and however they choose to shop, at a time when value is top of mind. This includes omnichannel campaign strategies that integrate media and promotions.

“The pandemic has increased the need for value not only for consumers, but for brands and retailers alike,” said Steven Boal, CEO of Quotient. “The demand for hybrid forms of shopping, along with shifting availabilities and local requirements, emphasized the need for flexible, effective and efficient media and promotions, which led to the significant growth in digital that we are seeing today.”

New verticals and partnerships

In the last year, Quotient expanded its retail network with new retailer partnerships including Shipt, grocery and convenience store retailer Hy-Vee, drugstore chain Rite Aid and convenience store chain 7-Eleven. Additionally, Quotient signed its first new retail partnership in the automotive vertical. Within its retail network, the company deepened its partnerships with retailers, which added solutions such as Sponsored Search and In-Lane digital promotions powered by Quotient to their solution set.

From a business offerings perspective, in 2020, Quotient partnered with Mandlik & Rhodes to offer brands and retailers a more strategic, transparent and efficient solution to clear digital coupons. Quotient also forged new partnerships with VIOOH to expand the digital out-of-home offering and began collaborating with TikTok as an approved advertiser, expanding its omnichannel offering into this growing platform.

Recognized success

Quotient’s creative prowess and integrated approach was highlighted with both a 2020 Effie award and a Silver Reggie award for its role in the “SNICKERS® World Wrestling Entertainment at Dollar General” campaign for Mars Wrigley. The campaign seamlessly combined three of Quotient’s core product offerings to drive its outstanding results: Social Influencer solution, a coupon offer and strategic paid media buys. Quotient also won the 2020 Martech Breakthrough Influencer Marketing Innovation award with its Social Influencer solution from over 2,750 submissions, which recognizes the best companies, technologies, products and services in marketing, advertising and sales technology.

Employee growth and corporate philanthropy

Quotient continued to strategically hire during the pandemic, increasing from approximately 955 employees in 2019 to 1,163 employees at the end of 2020. Women represent 60% of Quotient’s executive leadership team at a time when McKinsey reports only about 1 in 5 C-suite executives is a woman. At the end of 2020, Quotient’s global workforce was 48.1% female, up slightly over 2019. Nearly 38% of employees who hold a manager title and above are women, increased from 2019.

Key hires in the last year include Renee Cutright, Chief People Officer, and the appointment of Lorraine Hariton to the Board of Directors. Renee Cutright joined Quotient in February 2020 and is responsible for all aspects of human resources strategy, including recruitment, development, compensation and benefits, employee relations and culture. She joined Quotient from Nielsen where she served as SVP, Human Resources, North America Connect (Consumer), Global Bases and Neuroscience. Lorraine Hariton, appointed to Quotient’s Board of Directors in January 2021, currently serves as the CEO of Catalyst and is an experienced board director and brings expertise in digital transformation, strategy, enterprise sales and marketing.

“Our commitment to hiring the best, brightest and most diverse minds in the industry will continue into the rest of this year,” said Renee Cutright, Chief People Officer at Quotient. “We are proud of the strides we’ve made in ensuring that women are a core part of Quotient’s cultural makeup.”

In 2021, as part of Quotient’s ongoing effort to influence positive change in the communities it serves, the company launched a newly refocused corporate philanthropy program: Quotient for Change.Quotient for Change tackles critical issues at the foundational level to provide communities with tangible outcomes to leave a positive legacy for future generations. To further this goal, Quotient supports programs that advance these core pillars: Economic Stability, Technological Equity and Environmental Sustainability.Quotient for Change also features an employee matching gift program, paid time off for volunteering and an assortment of philanthropic activities offered both company-wide and in office.

About Quotient

Quotient (NYSE: QUOT) is the leading digital media and promotions technology company that creates cohesive omnichannel brand-building and sales-driving opportunities to deliver valuable outcomes for advertisers, retailers and consumers. The Quotient platform is powered by exclusive consumer spending data, location intelligence and purchase intent data to reach millions of shoppers daily and deliver measurable, incremental sales.

Quotient partners with leading advertisers and retailers, including Clorox, Procter & Gamble, General Mills, Unilever, Albertsons Companies, CVS, Dollar General and Peapod Digital Labs, a company of Ahold Delhaize USA. Quotient is headquartered in Mountain View, California, and has offices across the US as well as in Bangalore, Paris, London and Tel Aviv. For more information visit www.quotient.com

Brands2Life on behalf of Quotient

Jenna Becker

415-610-7500

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Marketing Online Retail Advertising Retail Communications Convenience Store Supermarket

MEDIA:

Logo
Logo
Posted on

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

  • Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint
  • Imsidolimab was generally well tolerated and no serious or severe adverse events were reported in the drug arm of the trial
  • AnaptysBio does not currently plan to conduct further clinical development in PPP
  • Advancement of imsidolimab to continue across 5 other distinct indications, including anticipated advancement into Phase 3 trial in generalized pustular psoriasis (GPP) in mid-2021

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe palmoplantar pustulosis (PPP), also known as the POPLAR trial, failed to meet its primary endpoint.

While further clinical development in PPP is not currently anticipated, AnaptysBio will continue development of imsidolimab in five other immuno-dermatological indications, including GPP, EGFRi-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne. Initiation of a Phase 3 clinical trial in GPP is anticipated during mid-2021 following completion of protocol alignment with the FDA.

“While the top-line results are disappointing, I would like to sincerely thank everyone involved in the POPLAR trial, including the patients, the investigators, their staff and our employees,” said Hamza Suria, president and chief executive officer of AnaptysBio. “Imsidolimab is currently being advanced in 5 other immuno-dermatology indications and we look forward to multiple additional clinical readouts during 2021 and 2022.”

POPLAR Trial Data

Top-line data from the POPLAR trial are as follows:

  • Mean baseline Palmoplantar Pustular Psoriasis Area Severity Index (PPPASI) scores were 16 for the 30 patients enrolled in the imsidolimab arm and 19 for the 29 patients enrolled in the placebo arm, with an overall average of 18. Mean baseline Palmoplantar Pustulosis Investigator Global Assessment (PPPIGA) was 3.1 for each arm. Patients were on average 50 years of age and 78% were female.
  • The primary endpoint of least-squares mean difference (LSMD) PPPASI improvement at week 16 (Day 113) was 6.1 for imsidolimab-treated patients and 6.3 for placebo-treated patients relative to their respective baselines, which has a p-value of 0.93 for the difference between the groups. Twenty-four patients completed the week 16 primary endpoint analysis in each arm of the trial.
LSMD PPPASI Relative to Baseline Imsidolimab Placebo Difference p-value
Week 4
(Day 29)		 -3.1 -3.1 0.0 0.99
Week 8
(Day 59)		 -4.6 -3.7 -0.9 0.62
Week 12
(Day 85)		 -5.6 -3.4 -2.2 0.25
Week 16
(Day 113, primary endpoint)		 -6.1 -6.3 0.2 0.93
  • Imsidolimab-treated patients had a mean PPPASI change from baseline of 5.78 or 38% improvement, while placebo-treated patients improved by 6.78 or 33% improvement, each relative to baseline. Percent PPPASI improvement versus baseline was numerically greater for imsidolimab-treated patients relative to placebo-treated patients at each study timepoint (Days 3, 8, 15, 22, 29, 43, 57, 71, 85 and 113), ranging from approximately 3% to 19%.
  • Nine (38%) patients achieved fifty percent PPPASI improvement (PPPASI50) and 4 (17%) patients achieved seventy five percent PPPASI improvement (PPPASI75) in the imsidolimab arm at week 16, while 12 (50%) and 3 (13%) achieved these responder thresholds in the placebo arm, respectively.
  • Five (21%) imsidolimab-treated patients achieved a PPPIGA score of zero (clear) or 1 (almost clear) at week 16 relative to 3 (13%) placebo-dosed patients.
Percent Improvement Relative To Baseline at
Week 16		 Imsidolimab Placebo
Mean PPPASI 38 % 33 %
PPPASI50 38 % 50 %
PPPASI75 17 % 13 %
PPPIGA 0/1 21 % 13 %
  • Imsidolimab was generally well-tolerated with a similar frequency of adverse events between treatment groups, and no severe or serious adverse events were observed in the imsidolimab arm. One severe and one serious adverse event was reported in the placebo-treated arm. The most common adverse events observed in the imsidolimab and placebo arms were three and four cases of mild nasopharyngitis, respectively, that were each deemed treatment unrelated.

POPLAR Phase 2 Trial Design

Fifty-nine PPP patients were enrolled in this trial at 36 sites located within North America and Europe. Patients were washed out of prior PPP therapy and no concomitant therapy was permitted during the trial.   Key inclusion criteria included age between 18 and 75 years, clinically confirmed ongoing moderate-to-severe PPP disease with minimum PPPIGA score of at least 3 (moderate), disease history of at least 3 months, and active pustules on palms and/or soles upon enrollment. Patients were treated with a 200mg subcutaneous induction dose of imsidolimab at Day 1, followed by monthly 100mg subcutaneous doses on Days 29, 57 and 85. The primary endpoint of this trial was mean change in PPPASI at week 16 relative to baseline and the estimator for between-group comparison was LSMD.   Baseline clinical assessments were conducted for each patient on Day 1 prior to imsidolimab dosing. Missing data was modeled using mixed model for repeated measures (MMRM) methodology.   

About Imsidolimab

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne. 

About AnaptysBio

AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including imsidolimab’s Phase 2 clinical trials in EGFRi and ichthyosis; the timing of initiation of imsidolimab’s Phase 2 clinical trials in hidradenitis suppurativa and acne; and the timing of initiation of imsidolimab’s Phase 3 clinical trial in GPP. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Contacts:
Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
[email protected]

 



Posted on

Avaya Introduces New Devices to Deliver Seamless Workstream Collaboration For Work From Anywhere Environments

Avaya Introduces New Devices to Deliver Seamless Workstream Collaboration For Work From Anywhere Environments

RALEIGH-DURHAM, N.C.–(BUSINESS WIRE)–Avaya (NYSE:AVYA), a global leader in solutions to enhance and simplify communications and collaboration, today announced new devices designed to significantly improve workstream collaboration. This includes a redesigned Avaya Vantage™ K155 with Amazon Alexa built-in, as well as a new Avaya IP Conference Phone B129, and Avaya Huddle Camera HC010.

The Avaya Vantage K155 has been redesigned to deliver a new level of simplicity and productivity for the home office worker, providing a horizontal touch screen and physical keypad. It is integrated with the Avaya Spaces™ workstream collaboration platform for immersive virtual communications and team collaboration, and extends Avaya’s Composable Home Office. Leveraging the Avaya OneCloud™ portfolio of UCaaS, CCaaS and CPaaS solutions, the Composable Home Office empowers businesses to create personalized and more productive home office experiences for employees and customer service agents.

Avaya Vantage K155 provides a high-definition camera, wideband audio, wireless connection and new “screen shifting” technology to enable new flexibility when participating in a meeting. Content, meeting participants, or both can be shifted to a larger screen based on the meeting dynamics at any given moment. For presenting content, one touch on the Avaya Vantage opens the same meeting on a laptop to enable presentation sharing options.

Avaya has integrated Amazon Alexa into the Avaya Vantage™ portfolio to provide easy access in the workplace to Alexa capabilities that many are accustomed to using in their home. With Alexa built-in, employees can now ask their Avaya Vantage to dial them into their next meeting or advise them of their calendar for the day — in addition to numerous other Alexa capabilities. Amazon Alexa is initially available on Avaya Vantage devices in the U.S. and Canada.

“Avaya has enabled thousands of workers to have the same level of productivity in their home office as in the workplace. As we start returning to the business office, the script is flipped – and we need to ensure employees continue to enjoy the same capabilities they are using at home,” said Anthony Bartolo, Avaya EVP and Chief Product Officer. “Amazon Alexa adds to the unique set of building blocks Avaya provides for our users to compose new employee and customer experiences.”

Additional new devices include:

  • Avaya IP Conference Phone B129, supporting meetings of up to 12 participants with Avaya OmniSound™ technology. It uses four microphones, beam forming technology, Bluetooth and USB connectivity to elevate any meeting and workstream collaboration experience.
  • The latest Avaya USB camera – the Avaya Huddle Camera HC010 provides a very cost-effective High-Definition camera option with 4X digital zoom, for professional quality video.

These new devices are available with the Avaya Device as a Service (DaaS) offering making them widely available with a small monthly fee.

Additional Resources

About Avaya

Businesses are built by the experiences they provide, and everyday millions of those experiences are delivered by Avaya Holdings Corp. (NYSE: AVYA). Avaya is shaping what’s next for the future of work, with innovation and partnerships that deliver game-changing business benefits. Our cloud communications solutions and multi-cloud application ecosystem power personalized, intelligent, and effortless customer and employee experiences to help achieve strategic ambitions and desired outcomes. Together, we are committed to help grow your business by delivering Experiences that Matter. Learn more at http://www.avaya.com/

Cautionary Note Regarding Forward-Looking Statements

This document contains certain “forward-looking statements.” All statements other than statements of historical fact are “forward-looking” statements for purposes of the U.S. federal and state securities laws. These statements may be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “our vision,” “plan,” “potential,” “preliminary,” “predict,” “should,” “will,” or “would” or the negative thereof or other variations thereof or comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. The factors are discussed in the Company’s Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) available at www.sec.gov, and may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. The Company cautions you that the list of important factors included in the Company’s SEC filings may not contain all of the material factors that are important to you. In addition, in light of these risks and uncertainties, the matters referred to in the forward-looking statements contained in this press release may not in fact occur. The Company undertakes no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

All trademarks identified by ®, TM, or SM are registered marks, trademarks, and service marks, respectively, of Avaya Inc. All other trademarks are the property of their respective owners.

Source: Avaya Newsroom

Alex Alias

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Data Management Technology Audio/Video Mobile/Wireless Software Internet Hardware

MEDIA:

Logo
Logo
Posted on

The 4Less Corp. Reports 2021 February Sales Were Up 41% Over Prior Years February Sales

LAS VEGAS, March 08, 2021 (GLOBE NEWSWIRE) — The 4Less Group, Inc. (FLES: OTCQB) is pleased to announce that its wholly owned subsidiary Auto Parts 4Less, Inc. (“4Less”, or the “Company”), the owner of Liftkits4less.com (www.liftkits4less.com) (“Liftkits”), has seen a 41% increase in gross revenue prior to returns on its liftkits4less.com website for the month of February 2021, as compared to the same month last year. 

“Reaching approximately 980k in gross revenue, prior to returns, is our best February in company’s history and a great way to kick-off the new year,” stated Christopher Davenport, President and CEO of Auto Parts 4Less, Inc. “Our strategy of strong branding and utilizing cutting edge technology is paying off as we move towards expanding our footprint with the upcoming launch of our flagship automotive parts only marketplace Autoparts4Less.com.”

Based on a potentially successful $15 million capital raise that the Company initiated the first of the year, the company expects they will be able to substantially increase Liftkits’ advertising and promotion budget from the approximate $100,000 spent in 2020. In doing so, the Company believes that their ecommerce site Liftkits will be potentially positioned to have a breakout year.

“With the extra net income we hope to achieve from the continued growth in sales from LiftKits, we expect to significantly offset our out of pocket costs to finish the development and launch of AutoParts4Less.com,” stated Tim Armes, President of The 4Less Group, Inc.

About The 4Less Group, Inc.   

Building off the knowledge and continued success of their present e-commerce website, liftkits4less.com, that targets the aftermarket automotive parts for Jeep Truck and SUV vehicles, The 4Less Group, Inc. (www.the4lessgroup.com ) is now focused on launching what they believe to be one of the world’s first automotive parts only multi-vendor marketplace under the URL AutoParts4Less.com. The projected MVP site launch will begin in early Summer 2021.

Also visit: www.autoparts4less.com as well as www.LiftKits4Less.com

CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including information about management’s view of the Company’s future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it can give no assurance that its forward-looking statements will prove to be correct. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause results to differ include but are not limited to, successful performance of internal plans, product or services development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The Company takes no obligation to update or correct (i) its own forward-looking statements, except as required by law, or (ii) those prepared by third parties that are not paid for by the Company.

For more information, contact:

Email: [email protected]

Investor Relations:

James S. Painter III
Emerging Markets Consulting, LLC.
[email protected]
321-206-6682



Posted on

FactSet launches the Truvalue Labs Sustainable Development Goals Monitor

Monitor designed to oversee corporate alignment to individual UN SDGs in real time

NORWALK, Conn., March 08, 2021 (GLOBE NEWSWIRE) — FactSet® (NYSE:FDS) (NASDAQ:FDS), a global provider of integrated financial information, analytical applications, and industry-leading service, has announced the launch of the Truvalue Labs® SDG Monitor, designed to enable investors and other interested parties to view the alignment of corporations around the globe to the UN Sustainable Development Goals (SDGs) in real time and review how this alignment differs in emphasis across regions.

Truvalue Labs, which was recently acquired by FactSet, has built a dataset underpinning the SDG Monitor that arises from more than 100,000 information sources in 13 languages, such as news, NGO reports, industry publications, trade journals and social media, and now covers more than 21,000 companies worldwide. The Monitor itself is free to use and is organized by country and/or region, allowing investors and investment professionals to see how companies in aggregate compare across regions in their alignment to the SDGs.

The analysis goes beyond the conventional approach of measuring SDG alignment via percentage of company revenue categorized by the goals and centers on externalities from a stakeholder perspective. For example, a clean energy car company that has a history of poor labor practices will be evaluated not just on the goal of clean energy, an area in which it generates revenue, but also on the goal of decent work, in which it does not. This focus on overall corporate effect – both positive and negative – offers users a differentiated perspective on how companies impact their environments.

According to the Truvalue ESG Investor Forum 2020 poll, 28% of respondents said their investment framework was currently aligned to the UN SDGs while 42% said they have plans to align. Moreover, 72% of respondents said social factors are the most difficult to analyze and integrate, with environmental ones next at 18%. These responses indicate that one of the keys to wider SDG adoption is access to better data for both the social and environmental pillars.

“FactSet is filling a significant data gap,” said Adam Salvatori, Global Head of ESG Client Solutions and Research at FactSet. “Our research and analysis are helping to lead the way by focusing on a more holistic external stakeholder assessment of ESG impact. The Truvalue Labs SDG Monitor is one major step on that journey.”

“The UN Global Compact drives business awareness and action in support of the Sustainable Development Goals by 2030. Fulfilling these ambitions will take an unprecedented effort by all sectors in society,” said Lila Karbassi, Chief of Programs at United Nations Global Compact. “We are delighted to see Truvalue Labs harnessing technology to provide a new layer of understanding around real world outcomes through the framework of the UN Sustainable Development Goals.”

The Truvalue Labs SDG Monitor is structured as a public service and is free to all. For more information, visit: https://sdg.factset.com.

About FactSet

FactSet® (NYSE:FDS | NASDAQ:FDS) delivers superior content, analytics, and flexible technology to help more than 138,000 users see and seize opportunity sooner. We give investment professionals the edge to outperform with informed insights, workflow solutions across the portfolio lifecycle, and industry-leading support from dedicated specialists. We’re proud to have been recognized with multiple awards for our analytical and data-driven solutions and repeatedly scored 100 by the Human Rights Campaign® Corporate Equality Index for our LGBTQ+ inclusive policies and practices. Subscribe to our thought leadership blog to get fresh insight delivered daily at insight.factset.com. Learn more at www.factset.com and follow us on Twitter: www.twitter.com/factset.



FactSet
Media
Jennifer Berlin
+1 617 330 4122
[email protected]

Media & Investor Relations Contact:
Rima Hyder
+1 857.265.7523
[email protected]

Posted on

IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials

IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C–(BUSINESS WIRE)–
IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials.

The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of telehealth technologies, virtual oversight, and digital patient engagement strategies. These capabilities enabled participants to be screened remotely to determine their risk status, to schedule an appointment at a nearby site, and to report potential COVID-19 symptoms and other study data remotely throughout the study.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Tor Constantino, IQVIA Media Relations ([email protected])

+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations ([email protected])

+1.973.257.7144

KEYWORDS: North Carolina Connecticut United States North America

INDUSTRY KEYWORDS: Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Posted on

Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients

  • First clinical trial of Aflibercept biosimilar to be completed in Korea
  • Supported by global formulation and process patents

 

DAEJEON, South Korea–(BUSINESS WIRE)–Alteogen Inc. (KOSDAQ:196170) announced that it has completed Phase 1 clinical trial of Eylea® Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened competitiveness through formulation patent registered in US, EU and Japan and filing of a process patent for PCT application.

Eylea® original product and Alteogen’s Eylea biosimilar (ALT-L9) were randomly assigned 1:1 to 28 patients with neovascular (wet) age-related macular degeneration; the study design was double blinded, active control, and parallel. No adverse drug-related reactions were observed in both groups and showed similar improvement effects in best corrected visual acuity (BCVA) and central subfield thickness (CST). In this phase 1 clinical trial, Alteogen confirmed the safety and efficacy of ALT-L9 were similar to that of Eylea®. Alteogen intends to prove the similarity of ALT-L9 with Eylea® through a registrational phase 3 clinical trial. The results from the phase 1 trial in Korea will support the design of the phase 3 trial and potentially provide a path to a shorter phase 3 trial.

Eylea® is a drug for the treatment of wet macular degeneration, one of the major senile blindness diseases, along with cataracts and glaucoma. Based on public reporting by Regeneron, the market size was about USD 4.947 Billion in 2020 in the United States alone, making this a blockbuster drug.

“Alteogen is uniquely positioned based on our patent position to launch a Eylea biosimilar upon substance patent expiration,” said Dr. Soon Jae Park, Chief Executive Officer of Alteogen. “Our patent position will give us potentially commercial first mover advantage.”

Altos Biologics Inc., a fully owned subsidiary of Alteogen will be responsible for all future clinical and commercial development.

About Alteogen Inc.

Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen’s portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV injection. The company was founded in 2008 and listed in KOSDAQ (196170.KQ).

For Alteogen – Media and Investors

Arun Swaminathan, Ph.D.

Chief Business Officer and Senior Vice President

Phone: (609) 937 8767

E-mail: [email protected]

KEYWORDS: Asia Pacific South Korea

INDUSTRY KEYWORDS: Health Clinical Trials Research Science Pharmaceutical Optical Biotechnology

MEDIA:

Logo
Logo
Posted on

DATA Communications Management Corp. Welcomes New President and Chief Executive Officer Richard Kellam

DATA Communications Management Corp. Welcomes New President and Chief Executive Officer Richard Kellam

BRAMPTON, Ontario–(BUSINESS WIRE)–
The board of directors of DATA Communications Management Corp. (“DCM” or the “Company”)(TSX:DCM), is pleased to announce the appointment of Richard Kellam as President and Chief Executive Officer of the Company, effective immediately. Kellam is replacing Gregory J. Cochrane who has been appointed Vice Chairman of DCM.

“Richard brings a wealth of general management, customer development and marketing experience through his 35-year international career with leading global companies,” said J.R. Kingsley Ward, chairman of DCM’s board of directors.

Kellam was recently the CEO of Advantage Group International, a leading consulting and business development organization working with the largest consumer goods and retail companies in 45 markets globally. Prior to Advantage, he was Senior Vice President of Global Sales and Marketing at Goodyear, in Akron Ohio. While at Goodyear, he took on additional responsibilities as Vice President of Emerging Markets, based in Dubai.

In addition, Kellam brings over 15 years experience with Mars, Incorporated, where he was the Global Chief Customer Officer, President of Petcare Europe, Managing Director UK Petcare and Market Director of Canada. Prior to Mars, he spent seven years with the Wm. Wrigley Jr. Company in marketing and general management roles of increasing responsibility, based in the United States, India, Malaysia, and Canada.

Kellam began his career as an Assistant Brand Manager with Playtex Limited and later served in marketing roles with Robin Hood Multifoods and Molson Canada.

“We are delighted to welcome Richard to DCM,” said Ward. “His global experience and successful track record will ensure our continued focus on our clients’ priorities as we continue to provide value-added solutions for their evolving needs.”

About DCM

DCM is a communication solutions partner that adds value for major companies across North America by creating more meaningful connections with their customers. DCM pairs customer insights and thought leadership with cutting edge products, modular enabling technology and services to power its clients’ go to market strategies. DCM helps its clients manage how their brands come to life, determine which channels are right for them, manage multimedia campaigns, deploy location specific and 1:1 marketing, execute custom loyalty programs, and fulfill their commercial printing needs all in one place.

DCM’s extensive experience has positioned it as an expert at providing communication solutions across many verticals, including the financial, retail, healthcare, consumer health, energy, and not for profit sectors. As a result of its locations throughout Canada and in the United States (Chicago, Illinois), it is able to meet its clients’ varying needs with scale, speed, and efficiency – no matter how large or complex the ask. DCM is able to deliver advanced data security, regulatory compliance, and bilingual communications, both in print and/or digital formats.

Additional information relating to DATA Communications Management Corp. is available on www.datacm.com, and in the disclosure documents filed by DATA Communications Management Corp. on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.

Mr. Richard Kellam

President & Chief Executive Officer

DATA Communications Management Corp.

Tel: (905) 791-3151

Mr. James E. Lorimer

Chief Financial Officer

DATA Communications Management Corp.

Tel: (905) 791-3151

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Professional Services Data Management Communications Technology Consulting Other Communications

MEDIA:

Logo
Logo
Posted on

Trex Company Appoints Gena C. Lovett to its Board of Directors

Trex Company Appoints Gena C. Lovett to its Board of Directors

Expands Board to 10 Members

WINCHESTER, Va.–(BUSINESS WIRE)–
Trex Company, Inc. (NYSE:TREX), the world’s #1 brand of composite decking and railing and leader in high-performance, low-maintenance and eco-friendly outdoor living products and a leading national provider of custom-engineered commercial railing systems, today announced the appointment of Gena C. Lovett as a new independent member of its Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005022/en/

Trex appoints Gena C. Lovett to its Board of Directors (Photo: Business Wire)

Trex appoints Gena C. Lovett to its Board of Directors (Photo: Business Wire)

Ms. Lovett is a seasoned operations executive with an extensive career in manufacturing at marquee companies. Most recently she served as Vice President of Operations for The Boeing Company’s defense sector, a $30 billion organization. Prior to that role, Ms. Lovett was Director of Manufacturing-Forging and later Chief Diversity Officer at Alcoa Corporation. From 1992 to 2007, she held a series of manufacturing positions at Ford Motor Company, moving up from Production Supervisor to Plant Manager. Ms. Lovett received her B.A. from Ohio State University and her M.B.A. from Baker College Center for Graduate Studies. She currently is pursuing her Ph.D. in Values Driven Leadership at Benedictine University.

Bryan H. Fairbanks, President and CEO, commented, “We are very pleased to welcome Gena to the Trex Board where she will be an excellent contributor to our continued success. Her extensive experience in large-scale manufacturing and operations will be very valuable as we complete our major capacity expansion program, and then turn our focus to improving manufacturing output and cost saving initiatives.”

About Trex Company

Trex Company is the world’s largest manufacturer of high-performance eco-friendly wood-alternative decking and railing with more than 25 years of product experience. Stocked in more than 6,700 retail locations worldwide, Trex outdoor living products offer a wide range of style options with fewer ongoing maintenance requirements than wood, as well as a truly environmentally responsible choice. Also, Trex is a leading national provider of custom-engineered railing systems for the commercial and multi-family market, including performing arts venues and sports stadiums. For more information, visit trex.com.

Dennis Schemm

Senior Vice President and CFO

540-542-6300

Lynn Morgen/Viktoriia Nakhla

AdvisIRy Partners

212-750-5800

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Architecture Specialty Forest Products Residential Building & Real Estate Natural Resources Commercial Building & Real Estate Other Manufacturing Construction & Property Retail Building Systems Landscape Home Goods Manufacturing

MEDIA:

Logo
Logo
Photo
Photo
Trex appoints Gena C. Lovett to its Board of Directors (Photo: Business Wire)
Posted on

Power Corporation to Announce Fourth Quarter and 2020 Financial Results on March 17, 2021

Canada NewsWire

MONTRÉAL, March 8, 2021 /CNW/ – Power Corporation of Canada (TSX: POW) (“Power Corporation”) will release its fourth quarter and 2020 financial results on Wednesday, March 17, 2021, after markets close.

R. Jeffrey Orr, President and Chief Executive Officer, and Gregory D. Tretiak, Executive Vice-President and Chief Financial Officer, will discuss the results in a conference call and live audio webcast on Thursday, March 18, 2021 at 8 a.m. (Eastern Time). A question and answer period with analysts will follow the presentation. Shareholders, investors and other stakeholders are welcome to participate on a listen-only basis.

The live audio webcast and presentation materials will be available at: https://powercorporation.com/en/investors/events-presentations/.

To listen via telephone, please dial 1-833-979-2697 toll-free in North America or 647-689-6826 for international calls and enter passcode 6298744#.

A replay of the conference call will be available from March 18, 2021 at 11 a.m. (Eastern Time) until May 13, 2021 by calling 1-800-585-8367 toll-free in North America or 416-621-4642 for international calls, using the access code 6298744#. A webcast archive will also be available on Power Corporation’s website.

About Power Corporation

Power Corporation is an international management and holding company that focuses on financial services in North America, Europe and Asia. Its core holdings are leading insurance, retirement, wealth management and investment businesses, including a portfolio of alternative asset investment platforms. To learn more, visit www.PowerCorporation.com.

SOURCE Power Corporation of Canada